Clinical trials leading to FDA approval demonstrated significant visceral fat reduction in patients with excess abdominal fat accumulation, validating what clinicians now see consistently in practice
Plants 11 , 1217 (2018)
Targeted Degradation of ZBP1 with Covalent PROTACs for Anti-Inflammatory Treatment of Infections
The most predominant drivers of breast cancer therapeutic resistance are summarized in Figure 4, which include a complex interplay of genetic factors (e.g., PTEN, TP53 mutations, HER2 amplification), epigenetic mechanisms (e.g., DNMT-mediated methylation, EZH2-driven H3K27me3), ncRNAs (e.g., HOTAIR, miR-21 with m6A modifications), apoptosis evasion (e.g., Bcl-2 upregulation), robust DNA repair (e.g., HR, NHEJ), and an immunosuppressive TIME (e.g., T cell exhaustion, MDSC infiltration, PD-L1 overexpression), particularly in TNBC and HER2-positive subtypes, highlighting multifaceted targets for precision oncology
By increasing the rate of fat oxidation, L-Carnitine also produces a secondary benefit: it spares your body's limited stores of muscle glycogen